

Third Quarter FY 2026 Earnings Results

April 2, 2026

Forward looking statements



Notice Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "projects," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2025. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Notice Regarding Non-GAAP Financial Measures


Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported pro forma results, adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.



Q3 FY 2026 Key Takeaways

Continued commercial and operational execution drives AngioDynamics' accelerated and profitable growth.

Continued Commercial Execution – Q3 FY 2026



Continued Execution

- Net sales of \$78.4M, +8.9% YoY growth
- Med Tech segment sales of \$37.3M, +19.0% YoY growth
- Med Device segment sales of \$41.1M, +1.1% YoY growth

Focus on Profitability

- Pro forma Adjusted EBITDA** of \$1.8M, an improvement of \$0.5M from Q3 FY 2025


Balance Sheet Strength

- Ended quarter with \$37.8M in Cash
- Zero debt with flexibility of revolving line of credit
- Used ~\$3.0M of cash in the quarter, slightly better than previously guided

Demonstrated Med Tech Growth Execution




Pro Forma Fiscal Year Net Sales (\$M)




Q3 FY 2026 Financial Snapshot




Net Sales



Segment Revenue Contribution



Segment Gross Margin



Med Tech - Auryon



Combination of Auryon's best-in-class technology and our commercial strategy have positioned Auryon as a consistently high-growth platform being supported by superior outcomes and ongoing investment to expand applicability



Period	Sales	YoY Growth
Q3 FY 2026	\$16.3M	17.9%

- Continued share capture through commercial execution
- Ongoing penetration into hospital setting provides higher ASPs and improving margins
- AMBITION BTK RCT and Registry ongoing

Med Tech – Thrombus Management



Combination of AlphaVac and AngioVac represent a strong, highly competitive mechanical thrombectomy portfolio which continues to take market share driven by expanded joint commercial strategy



Q3 FY 2026	Sales	YoY Growth
AlphaVac	\$4.4M	47.4%
AngioVac	\$7.2M	5.0%
Total Mech Thromb.	\$11.5M	17.9%
Unifuse	\$1.8M	27.5%
Total Thrombus Mgmt.	\$13.3M	19.1%

AlphaVac

- Second quarter of 40%+ YoY growth driven by growth in PE
- Sequential revenue increased by roughly \$850,000, a ~24% increase
- First patients enrolled in APEX-Return IDE study in March 2026

AngioVac

- FDA IDE approval obtained for PAVE clinical study in right-sided infective endocarditis (RSIE)

Med Tech - NanoKnife



Adoption has continued to accelerate within Prostate as this novel therapy gains traction following receipt of FDA clearance in Dec 2024



NANOKNIFE
Irreversible Electroporation (IRE) PROSTATE

Q3 FY 2026	Sales	YoY Growth
Disposables	\$5.9M	20.0%
Capital	\$1.7M	24.9%
Total	\$7.6M	21.0%


- Continued demand for NanoKnife for prostate driving increased utilization
- Prostate Tissue CPT Category 1 Code, effective Jan. 1, 2026. Streamlines reimbursement for healthcare providers performing irreversible electroporation (IRE) ablation procedures

Compelling FY 2026 Financial Outlook

supported by balance sheet strength



FY 2026 Net Sales (\$M)



FY 2026 Financial Guidance*

Metric	Action	Current Guidance	Prior Guidance
Net Sales	Increased	\$313.5 - \$315.5M	\$312 - \$314M
<i>Med Tech Net Sales Growth</i>	<i>Increased</i>	<i>+15% - 17%</i>	<i>+14 - 16%</i>
<i>Med Device Net Sales Growth</i>	<i>Increased</i>	<i>Approx. 1%</i>	<i>+0 - 1%</i>
Gross Margin	Unchanged	53.5 - 55.5%	53.5 - 55.5%
Adjusted EBITDA	Increased	+\$10.0 - \$12.0M	+\$8.0 - \$10.0M
Adjusted EPS	Increased	(\$0.30) - (\$0.23)	(\$0.33) - (\$0.23)

- **FY 2026 Cash Guidance:** Proactively increasing inventory may result in additional cash use in Q4, bringing full-year operating cash to slightly negative, down from prior positive guidance.
- **\$37.8M** in Cash at Feb 28, 2026
- **Zero debt on balance sheet with flexibility** from revolving line of credit



Appendix

Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements



(in thousand, except per share data)

	Three Months Ended					
	Actual ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma
	Feb 28, 2026	Feb 28, 2026	Feb 28, 2026	Feb 28, 2025	Feb 28, 2025	Feb 28, 2025
		(unaudited)			(unaudited)	
Net sales	\$ 78,423	(2)	\$ 78,421	\$ 72,004	9	\$ 72,013
Cost of sales (exclusive of intangible amortization)	36,944	—	36,944	33,147	6	33,153
Gross margin	41,479	(2)	41,477	38,857	3	38,860
% of net sales	52.9 %		52.9 %	54.0 %		54.0 %
Operating expenses						
Research and development	7,084	—	7,084	6,913	—	6,913
Sales and marketing	27,437	—	27,437	25,504	—	25,504
General and administrative	10,719	—	10,719	10,490	—	10,490
Amortization of intangibles	2,668	—	2,668	2,598	—	2,598
Change in fair value of contingent consideration	—	—	—	40	—	40
Acquisition, restructuring and other items, net	6,522	—	6,522	3,286	(3)	3,283
Total operating expenses	54,430	—	54,430	48,831	(3)	48,828
Operating loss	(12,951)	(2)	(12,953)	(9,974)	6	(9,968)
Interest income (expense), net	(88)	—	(88)	135	—	135
Other income (expense), net	4,967	(5,000)	(33)	5,430	(5,500)	(70)
Total other income (expense), net	4,879	(5,000)	(121)	5,565	(5,500)	65
Loss before income tax (benefit) expense	(8,072)	(5,002)	(13,074)	(4,409)	(5,494)	(9,903)
Income tax (benefit) expense	12	—	12	(2)	—	(2)
Net loss	\$ (8,084)	\$ (5,002)	\$ (13,086)	\$ (4,407)	\$ (5,494)	\$ (9,901)
Loss per share						
Basic	\$ (0.19)		\$ (0.31)	\$ (0.11)		\$ (0.24)
Diluted	\$ (0.19)		\$ (0.31)	\$ (0.11)		\$ (0.24)
Weighted average shares outstanding						
Basic	41,596		41,596	40,853		40,853
Diluted	41,596		41,596	40,853		40,853

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrex products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2026 and February 28, 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

	Nine Months Ended					
	Actual ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma
	Feb 28, 2026	Feb 28, 2026	Feb 28, 2026	Feb 28, 2025	Feb 28, 2025	Feb 28, 2025
		(unaudited)			(unaudited)	
Net sales	\$ 233,567	(2)	\$ 233,565	\$ 212,340	188	\$ 212,528
Cost of sales (exclusive of intangible amortization)	105,448	—	105,448	96,853	155	97,008
Gross margin	128,119	(2)	128,117	115,487	33	115,520
% of net sales	54.9 %		54.9 %	54.4 %		54.4 %
Operating expenses						
Research and development	21,269	—	21,269	19,632	—	19,632
Sales and marketing	82,278	—	82,278	76,698	—	76,698
General and administrative	33,425	—	33,425	31,856	—	31,856
Amortization of intangibles	7,964	—	7,964	7,730	—	7,730
Change in fair value of contingent consideration	—	—	—	272	—	272
Acquisition, restructuring and other items, net	12,915	—	12,915	13,465	161	13,626
Total operating expenses	157,851	—	157,851	149,653	161	149,814
Operating loss	(29,732)	(2)	(29,734)	(34,166)	(128)	(34,294)
Interest income (expense), net	(194)	—	(194)	975	—	975
Other income (expense), net	4,661	(5,000)	(339)	5,269	(5,500)	(231)
Total other income (expense), net	4,467	(5,000)	(533)	6,244	(5,500)	744
Loss before income tax expense	(25,265)	(5,002)	(30,267)	(27,922)	(5,628)	(33,550)
Income tax expense	72	—	72	21	—	21
Net loss	\$ (25,337)	\$ (5,002)	\$ (30,339)	\$ (27,943)	\$ (5,628)	\$ (33,571)
Loss per share						
Basic	\$ (0.61)		\$ (0.73)	\$ (0.68)		\$ (0.82)
Diluted	\$ (0.61)		\$ (0.73)	\$ (0.68)		\$ (0.82)
Weighted average shares outstanding						
Basic	41,467		41,467	40,809		40,809
Diluted	41,467		41,467	40,809		40,809

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrex products ("the Businesses") as of February 29, 2024, for the nine months ended February 28, 2026 and February 28, 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

Reconciliation of Net Loss to Non-GAAP Adjusted Net Income (Loss) and EPS and Pro Forma Adjusted Net Loss and EPS

(in thousands, except per share data)

	Three Months Ended					
	Actual ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma
	Feb 28, 2026	Feb 28, 2026	Feb 28, 2026	Feb 28, 2025	Feb 28, 2025	Feb 28, 2025
	(unaudited)			(unaudited)		
Net loss	\$ (8,084)	\$ (5,002)	\$ (13,086)	\$ (4,407)	\$ (5,494)	\$ (9,901)
Amortization of intangibles	2,668	—	2,668	2,598	—	2,598
Change in fair value of contingent consideration	—	—	—	40	—	40
Acquisition, restructuring and other items, net ⁽³⁾	6,522	—	6,522	3,286	(3)	3,283
Tax effect of non-GAAP items ⁽⁴⁾	(245)	1,150	905	(350)	1,264	914
Adjusted net income (loss)	\$ 861	\$ (3,852)	\$ (2,991)	\$ 1,167	\$ (4,233)	\$ (3,066)

	Three Months Ended					
	Actual ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma
	Feb 28, 2026	Feb 28, 2026	Feb 28, 2026	Feb 28, 2025	Feb 28, 2025	Feb 28, 2025
	(unaudited)			(unaudited)		
Diluted loss per share	\$ (0.19)	\$ (0.12)	\$ (0.31)	\$ (0.11)	\$ (0.13)	\$ (0.24)
Amortization of intangibles	0.06	—	0.06	0.06	—	0.06
Change in fair value of contingent consideration	—	—	—	0.01	—	0.01
Acquisition, restructuring and other items, net ⁽³⁾	0.16	—	0.16	0.08	(0.01)	0.07
Tax effect of non-GAAP items ⁽⁴⁾	(0.01)	0.03	0.02	(0.01)	0.03	0.02
Adjusted diluted income (loss) per share	\$ 0.02	\$ (0.09)	\$ (0.07)	\$ 0.03	\$ (0.11)	\$ (0.08)

Adjusted diluted sharecount⁽⁵⁾ 43,752 41,596 41,596 42,091 40,853 40,853

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2026 and 2025, respectively.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(4) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended February 28, 2026 and 2025.

(5) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

Reconciliation of Net Loss and non-GAAP Pro Forma Adjusted Net Loss to Adjusted EBITDA and Pro Forma Adjusted EBITDA

(in thousands)



	Three Months Ended					
	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma
	Feb 28, 2026	Feb 28, 2026	Feb 28, 2026	Feb 28, 2025	Feb 28, 2025	Feb 28, 2025
	(unaudited)			(unaudited)		
Net loss	\$ (8,084)	\$ (5,002)	\$ (13,086)	\$ (4,407)	\$ (5,494)	\$ (9,901)
Income tax expense	12	—	12	(2)	—	(2)
Interest expense (income), net	88	—	88	(135)	—	(135)
Depreciation and amortization	5,591	—	5,591	6,319	—	6,319
Change in fair value of contingent consideration	—	—	—	40	—	40
Stock based compensation	2,684	—	2,684	2,398	—	2,398
Acquisition, restructuring and other items, net ⁽³⁾	6,522	—	6,522	2,623	(3)	2,620
Adjusted EBITDA	\$ 6,813	\$ (5,002)	\$ 1,811	\$ 6,836	\$ (5,497)	\$ 1,339

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2026 and 2025, respectively.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

Reconciliation of Net Loss to Non-GAAP Adjusted Net Loss and EPS and Pro Forma Adjusted Net Loss and EPS

(in thousands, except per share data)

	Nine Months Ended					
	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma
	Feb 28, 2026	Feb 28, 2026	Feb 28, 2026	Feb 28, 2025	Feb 28, 2025	Feb 28, 2025
		(unaudited)		(unaudited)		
Net loss	\$ (25,337)	\$ (5,002)	\$ (30,339)	\$ (27,943)	\$ (5,628)	\$ (33,571)
Amortization of intangibles	7,964	—	7,964	7,730	—	7,730
Change in fair value of contingent consideration	—	—	—	272	—	272
Acquisition, restructuring and other items, net ⁽³⁾	12,915	—	12,915	13,465	161	13,626
Tax effect of non-GAAP items ⁽⁴⁾	1,081	1,150	2,231	1,506	1,257	2,763
Adjusted net loss	<u>\$ (3,377)</u>	<u>\$ (3,852)</u>	<u>\$ (7,229)</u>	<u>\$ (4,970)</u>	<u>\$ (4,210)</u>	<u>\$ (9,180)</u>

	Nine Months Ended					
	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma
	Feb 28, 2026	Feb 28, 2026	Feb 28, 2026	Feb 28, 2025	Feb 28, 2025	Feb 28, 2025
		(unaudited)		(unaudited)		
Diluted loss per share	\$ (0.61)	\$ (0.12)	(0.73)	(0.68)	\$ (0.14)	(0.82)
Amortization of intangibles	0.19	—	0.19	0.19	—	0.19
Change in fair value of contingent consideration	—	—	—	0.01	—	0.01
Acquisition, restructuring and other items, net ⁽³⁾	0.31	—	0.31	0.32	\$ 0.01	0.33
Tax effect of non-GAAP items ⁽⁴⁾	0.03	0.03	0.06	0.04	\$ 0.03	0.07
Adjusted diluted loss per share	<u>\$ (0.08)</u>	<u>\$ (0.09)</u>	<u>\$ (0.17)</u>	<u>\$ (0.12)</u>	<u>\$ (0.10)</u>	<u>\$ (0.22)</u>

Adjusted diluted sharecount ⁽⁵⁾ 41,467 41,467 41,467 40,809 40,809 40,809

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the nine months ended February 28, 2026 and 2025, respectively.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(4) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended February 28, 2026 and 2025.

(5) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

Reconciliation of Net Loss and Non-GAAP Pro Forma Adjusted Net Loss to Adjusted EBITDA and Pro Forma Adjusted EBITDA



(in thousands)

	Nine Months Ended					
	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾	Pro Forma
	Feb 28, 2026	Feb 28, 2026	Feb 28, 2026	Feb 28, 2025	Feb 28, 2025	Feb 28, 2025
		(unaudited)		(unaudited)		
Net loss	\$ (25,337)	\$ (5,002)	\$ (30,339)	\$ (27,943)	\$ (5,628)	\$ (33,571)
Income tax expense	72	—	\$ 72	21	—	\$ 21
Interest expense (income), net	194	—	\$ 194	(975)	—	\$ (975)
Depreciation and amortization	17,358	—	\$ 17,358	19,967	—	\$ 19,967
Change in fair value of contingent consideration	—	—	\$ —	272	—	\$ 272
Stock based compensation	10,045	—	\$ 10,045	8,131	—	\$ 8,131
Acquisition, restructuring and other items, net ⁽³⁾	12,578	—	\$ 12,578	10,239	161	\$ 10,400
Adjusted EBITDA	<u>\$ 14,910</u>	<u>\$ (5,002)</u>	<u>\$ 9,908</u>	<u>\$ 9,712</u>	<u>\$ (5,467)</u>	<u>\$ 4,245</u>

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the nine months ended February 28, 2026 and 2025, respectively.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

Detail of “Acquisition, Restructuring and Other Items, net”



(in thousands)

	Three Months Ended		Nine Months Ended	
	Feb 28, 2026	Feb 28, 2025	Feb 28, 2026	Feb 28, 2025
	(unaudited)		(unaudited)	
Legal ⁽¹⁾	\$ 146	\$ —	\$ 1,831	\$ 406
Mergers and acquisitions	—	—	—	737
Plant closure ⁽²⁾	5,195	3,130	9,911	11,820
Transition service agreement ⁽³⁾	(555)	(463)	(1,523)	(1,424)
CEO retirement and transition ⁽⁴⁾	870	—	870	—
Other	866	619	1,826	1,926
Total	\$ 6,522	\$ 3,286	\$ 12,915	\$ 13,465

(1) Legal expenses related to litigation that is outside the normal course of business.

(2) Plant closure expense, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024.

(3) Transition services agreements that were entered into with Merit and Spectrum.

(4) CEO retirement and transition expenses related to the CEO search and retention agreements with the Company's executive leadership team.

Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category



(in thousands)

	Three Months Ended								
	Pro Forma Adjustments ⁽²⁾		Pro Forma	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾		Pro Forma	Actual	Pro Forma
	Feb 28, 2026	Feb 28, 2026	Feb 28, 2026	Feb 28, 2025	Feb 28, 2025	Feb 28, 2025	% Growth	% Growth	
	(unaudited)			(unaudited)					
Net Sales									
Med Tech	\$ 37,282	\$ —	\$ 37,282	\$ 31,341	\$ —	\$ 31,341	19.0%	19.0%	
Med Device	41,141	(2)	41,139	40,663	9	40,672	1.2%	1.1%	
	<u>\$ 78,423</u>	<u>\$ (2)</u>	<u>\$ 78,421</u>	<u>\$ 72,004</u>	<u>\$ 9</u>	<u>\$ 72,013</u>	<u>8.9%</u>	<u>8.9%</u>	
Net Sales									
United States	\$ 67,278	(2)	\$ 67,276	\$ 61,340	4	\$ 61,344	9.7%	9.7%	
International	11,145	—	11,145	10,664	5	10,669	4.5%	4.5%	
	<u>\$ 78,423</u>	<u>\$ (2)</u>	<u>\$ 78,421</u>	<u>\$ 72,004</u>	<u>\$ 9</u>	<u>\$ 72,013</u>	<u>8.9%</u>	<u>8.9%</u>	

	Three Months Ended								
	Pro Forma Adjustments ⁽²⁾		Pro Forma	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾		Pro Forma	Actual	Pro Forma
	Feb 28, 2026	Feb 28, 2026	Feb 28, 2026	Feb 28, 2025	Feb 28, 2025	Feb 28, 2025	% Change	% Change	
	(unaudited)			(unaudited)					
Med Tech	\$ 23,292	\$ —	\$ 23,292	\$ 19,588	\$ —	\$ 19,588	18.9 %	18.9 %	
Gross margin % of sales	62.5 %		62.5 %	62.5 %		62.5 %			
Med Device	\$ 18,187	(2)	\$ 18,185	\$ 19,269	3	\$ 19,272	(5.6)%	(5.6)%	
Gross margin % of sales	44.2 %		44.2 %	47.4 %		47.4 %			
Total	\$ 41,479	(2)	\$ 41,477	\$ 38,857	3	\$ 38,860	6.7 %	6.7 %	
Gross margin % of sales	52.9 %		52.9 %	54.0 %		54.0 %			

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

	Nine Months Ended								
	Pro Forma Adjustments ⁽²⁾		Pro Forma	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾		Pro Forma	Actual	Pro Forma
	Feb 28, 2026	Feb 28, 2026	Feb 28, 2026	Feb 28, 2025	Feb 28, 2025	Feb 28, 2025	% Growth	% Growth	
	(unaudited)			(unaudited)					
Net Sales									
Med Tech	\$ 108,196	\$ —	\$ 108,196	\$ 90,863	\$ —	\$ 90,863	19.1%	19.1%	
Med Device	125,371	(2)	125,369	121,477	188	121,665	3.2%	3.0%	
	<u>\$ 233,567</u>	<u>\$ (2)</u>	<u>\$ 233,565</u>	<u>\$ 212,340</u>	<u>\$ 188</u>	<u>\$ 212,528</u>	<u>10.0%</u>	<u>9.9%</u>	
Net Sales									
United States	\$ 201,328	(2)	\$ 201,326	\$ 183,499	14	\$ 183,513	9.7%	9.7%	
International	32,239	—	32,239	28,841	174	29,015	11.8%	11.1%	
	<u>\$ 233,567</u>	<u>\$ (2)</u>	<u>\$ 233,565</u>	<u>\$ 212,340</u>	<u>\$ 188</u>	<u>\$ 212,528</u>	<u>10.0%</u>	<u>9.9%</u>	

	Nine Months Ended								
	Pro Forma Adjustments ⁽²⁾		Pro Forma	As Reported ⁽¹⁾	Pro Forma Adjustments ⁽²⁾		Pro Forma	Actual	Pro Forma
	Feb 28, 2026	Feb 28, 2026	Feb 28, 2026	Feb 28, 2025	Feb 28, 2025	Feb 28, 2025	% Change	% Change	
	(unaudited)			(unaudited)					
Med Tech	\$ 68,500	\$ —	\$ 68,500	\$ 57,398	\$ —	\$ 57,398	19.3 %	19.3 %	
Gross margin % of sales	63.3 %		63.3 %	63.2 %		63.2 %			
Med Device	\$ 59,619	(2)	\$ 59,617	\$ 58,089	33	\$ 58,122	2.6 %	2.6 %	
Gross margin % of sales	47.6 %		47.6 %	47.8 %		47.8 %			
Total	\$ 128,119	(2)	\$ 128,117	\$ 115,487	33	\$ 115,520	10.9 %	10.9 %	
Gross margin % of sales	54.9 %		54.9 %	54.4 %		54.4 %			

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the nine months ended February 28, 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.